HCA
CGEM icon

Harbor Capital Advisors’s Cullinan Oncology CGEM Stock Holding History

Harbor Capital Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,747
Closed -$374K – 1427
2024
Q4 		$374K Buy
30,747
+9,385
+44% +$135K 0.02% 595
2024
Q3 		$358K Buy
21,362
+3,881
+22% +$68.8K 0.02% 616
2024
Q2 		$305K Buy
17,481
+4,941
+39% +$105K 0.02% 606
2024
Q1 		$214K Sell
12,540
-1,923
-13% -$29.7K 0.03% 587
2023
Q4 		$147K Buy
14,463
+4,197
+41% +$37.2K 0.03% 393
2023
Q3 		$92.9K Sell
10,266
-3,628
-26% -$37.8K 0.02% 421
2023
Q2 		$149K Buy
+13,894
New +$148K 0.03% 395

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Harbor Capital Advisors's CGEM Position: Q1 2025 in Review

Harbor Capital Advisors sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 30,747 shares — an estimated $374K sold.

Harbor Capital Advisors first reported a position in CGEM in Q2 2023 and held it in 7 quarters. The position peaked at $374K in Q4 2024. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Harbor Capital Advisors reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 30,747 Cullinan Oncology shares in Q1 2025, an estimated $374K.
  • Harbor Capital Advisors first reported a position in Cullinan Oncology in Q2 2023 and held it in 7 quarters.
  • Harbor Capital Advisors's Cullinan Oncology position peaked at $374K in Q4 2024.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.